Old Mission Investment Co LLC Invests $502,000 in Amgen Inc. $AMGN

Old Mission Investment Co LLC bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,385 shares of the medical research company’s stock, valued at approximately $502,000.

A number of other hedge funds have also recently bought and sold shares of the company. Dogwood Wealth Management LLC grew its stake in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares during the last quarter. Anfield Capital Management LLC lifted its stake in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the last quarter. Tower View Wealth Management LLC boosted its holdings in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after buying an additional 63 shares in the last quarter. Manning & Napier Advisors LLC grew its position in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the last quarter. Finally, Evergreen Advisors LLC acquired a new position in Amgen in the first quarter worth approximately $37,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

AMGN stock opened at $437.23 on Friday. The company has a market capitalization of $236.38 billion, a price-to-earnings ratio of 27.17, a P/E/G ratio of 3.20 and a beta of 0.43. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $447.03. The firm has a 50 day moving average of $397.39 and a two-hundred day moving average of $367.15. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period last year, the company earned $6.02 earnings per share. The business’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen’s dividend payout ratio (DPR) is 62.65%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. The Goldman Sachs Group set a $389.00 target price on Amgen in a research report on Friday, June 5th. Royal Bank Of Canada increased their price target on Amgen from $370.00 to $400.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Morgan Stanley reissued an “overweight” rating and issued a $362.00 price target on shares of Amgen in a research note on Wednesday, August 19th. Canaccord Genuity Group upped their price objective on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Finally, Citigroup raised their target price on shares of Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $381.68.

Insider Activity at Amgen

In other news, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 6,222 shares of company stock worth $2,540,926. Company insiders own 0.85% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha data could expand its addressable market. Amgen reported that Repatha reduced all-cause mortality by 20% in a prespecified analysis of the Phase 3 VESALIUS-CV trial, which studied more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. Earlier use could support broader adoption of the cardiovascular drug. Amgen Repatha VESALIUS-CV article
• Positive Sentiment: MariTide retains a potential convenience advantage in obesity treatment. Amgen’s investigational therapy could require less-frequent dosing than competing treatments from Eli Lilly and Novo Nordisk. That feature may help differentiate MariTide if its clinical and regulatory profile supports approval, although competition in the market remains intense. Amgen MariTide obesity article
• Neutral Sentiment: Shares had recently approached a 52-week high. Recent strength followed better-than-expected quarterly earnings and raised 2026 guidance, but the stock’s elevated valuation and gains left it more vulnerable to profit-taking when adverse regulatory news emerged. Amgen stock and 2026 guidance article
• Negative Sentiment: U.K. action against Tavneos intensified regulatory risk. The U.K. regulator suspended Tavneos for new patients and indicated a path toward revoking its authorization in March 2027, saying the drug’s benefit-risk balance was no longer favorable and that its pivotal efficacy study could not be relied upon. This compounds the FDA’s April proposal to withdraw U.S. approval over effectiveness, application-disclosure and liver-safety concerns, raising the possibility of broader loss of value for the drug. Amgen Tavneos regulatory pressure article
• Negative Sentiment: Insider selling added a modest sentiment headwind. Reported insider transactions showed seven sales and no purchases over the past six months, though these trades are less significant than the Tavneos developments. Amgen trading disclosures article

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.